Filing Flows › Arcus Biosciences (RCUS) › Stock forecast & fair value
Arcus Biosciences (RCUS) stock forecast and price target
Arcus Biosciences (RCUS) trades at $18.28. 12 analysts' median price target is $45.00 (+146%), from $23.00 to $50.00.
Arcus Biosciences' latest quarter
Arcus Biosciences, Q3 2026: revenue $9.0M (-65% year over year), net loss $128M, operating cash flow −$88.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for RCUS stock?
The median of 12 analysts' 12-month targets is $45.00, +146% from $18.28; the range is $23.00 to $50.00. The average rating is strong buy.
Does Arcus Biosciences usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is RCUS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.